Deutsche Märkte schließen in 5 Stunden 6 Minuten

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Echtzeitpreis. Währung in DKK
Zur Watchlist hinzufügen
437,15+2,00 (+0,46%)
Ab 12:24PM MESZ. Markt geöffnet.

Novo Nordisk A/S

Novo Allé
Bagsvaerd 2880
Denmark
45 44 44 88 88
http://www.novonordisk.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter43.526

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Lars Fruergaard JørgensenPres, CEO & Member of Management Board35,1MN/A1966
Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management Board11,6MN/A1971
Dr. Mads Krogsgaard ThomsenExec. VP, Chief Scientific Officer & Member of the Management Board16,1MN/A1960
Mr. Henrik Ehlers WulffExec. VP, Head of Product Supply, Quality & IT and Member of the Management Board13,4MN/A1970
Ms. Camilla SylvestExec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board11,7MN/A1972
Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in DKK.

Beschreibung

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate Governance

Novo Nordisk A/Ss ISS Governance QualityScore, Stand 9. Dezember 2019, lautet 4. Die grundlegenden Scores sind Audit: 1, Vorstand: 3, Shareholderrechte: 10, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.
Mit Yahoo Nutzung stimmen Sie zu, dass Yahoo und Partner Cookies für Personalisierungs- und andere Zwecke nutzen